Advertisement

Topics

Focus on Therapeutic Outcomes, Inc. Company Profile

08:36 EST 16th November 2018 | BioPortfolio


News Articles [268 Associated News Articles listed on BioPortfolio]

ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was ...

PARIS and TARRYTOWN, N.Y., Nov. 11, 2018 /PRNewswire/ -- New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Read more...

Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent (alirocumab) was associated with fewer deaths from any cause

ODYSSEY OUTCOMES investigators highlight at AHA that Praluent (alirocumab) was associated with fewer deaths from any cause Mortality risk reduction greater in patients treated for at least 3 years...

Shire, Takeda Come to Terms on $62B Acquisition Deal

Takeda Pharmaceutical has won its two-month quest to acquire Shire, with the boards of both companies coming to terms on an approximately £46 billion ($62 billion) purchase of the Dublin-headquar...

Rethinking psychedlics: Study looks at the practice of microdosing to ease anxiety and sharpen focus

New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial

New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial Praluent significantly reduced major adverse cardio...

Jazz Pharma Sells Prialt Rights to TerSera Therapeutics

To focus resources on core therapeutic areas of sleep medicine and hematology/oncology

Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis

Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood testReal-world data add to the ...

REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint

REDUCE-IT Is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific t...

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Anecream [Focus Health Group]

Drug Facts:

Anecream 5 [Focus Health Group]

Drug Facts:

Axe sharp focus invisible solid [Conopco Inc. d/b/a Unilever]

Axe Sharp Focus Antiperspirant Deodorant

Axe [Conopco Inc. d/b/a Unilever]

Axe Dry Sharp Focus Antiperspirant Deodorant

Snowskin sunscreen [Skin Alive, Ltd.]

SNOWSKIN SUNSCREEN SPF 30+

PubMed Articles [1192 Associated PubMed Articles listed on BioPortfolio]

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial.

The ODYSSEY OUTCOMES trial compared alirocumab with placebo, added to high-intensity or maximum tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced t...

NECESSITY OF MULTIMODAL TREATMENT OF ACROMEGALY AND OUTCOMES.

Uncontrolled acromegaly is associated with increased morbidity and mortality. Despite multimodal therapeutic options, adequate control can be challenging and lead to prolonged exposure to growth hormo...

Keeping a Focus on Research Ethics.

Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview.

: The right ventricle has become increasingly studied in cardiovascular research. In this article, we describe specific pathophysiological characteristics of the right ventricle, with special focus on...

New therapeutic approaches for hidradenitis suppurativa.

Hidradenitis suppurativa (HS) is a chronic cutaneous disease with a prevalence ranging between 0.05 % and 4 % in the general population. The clinical presentation features painful, inflammatory nodule...

Clinical Trials [3177 Associated Clinical Trials listed on BioPortfolio]

Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads

This non-intervention qualitative study will use focus groups to assess the feasibility and acceptability of a proposed intervention for a future study. The focus group will discuss a pote...

MIROCALS: Modifying Immune Response and OutComes in ALS

MIROCALS is a phase II study of ld-IL-2 as a therapeutic agent for ALS. A randomized (1:1), placebo-controlled, double-blind, parallel group trial will be carried out to assess ld-IL-2 saf...

Attentional Focus Influence During Cranio-Cervical Flexion Test

The purpose of this study is to termine if a different attentional focus would alter the motor control in cervical muscles during the cranio-cervical test.

Current Treatment of HCV Infection After HSCT

The availability of novel therapies with DAAs might prompt clinicians caring for HSCT recipients with HCV infection to prescribe the treatment more frequently and possibly earlier after HS...

Extra - Abdominal Versus Intra - Abdominal Repair of the Uterine Incision at Cesarean Section

To evaluate the effects of extra-abdominal repair of the uterine incision compared to intra-abdominal repair, and to study is there superiority of one technique over the other in terms of ...

Companies [1750 Associated Companies listed on BioPortfolio]

Health Outcomes Sciences

Health Outcomes Sciences is propelling the practice of precision medicine through its patented content enablement platform, ePRISM®, which translates scientific models into aut...

fOCUS Pharmaceuticals, LLC

fOCUS Pharmaceuticals is a privately held generic and branded pharmaceutical company specializing in the research and development of prescription dermatology products. Our primary focus are in the are...

Social Solutions Global, Inc.

Social Solutions Global, Inc., creators of Efforts to Outcomes (ETO®) software, equips over 16,000 programs with web-based data-tracking and outcomes-oriented case management t...

Focus on Therapeutic Outcomes, Inc.

ProStrakan

ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in ma...

More Information about "Focus on Therapeutic Outcomes, Inc." on BioPortfolio

We have published hundreds of Focus on Therapeutic Outcomes, Inc. news stories on BioPortfolio along with dozens of Focus on Therapeutic Outcomes, Inc. Clinical Trials and PubMed Articles about Focus on Therapeutic Outcomes, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Focus on Therapeutic Outcomes, Inc. Companies in our database. You can also find out about relevant Focus on Therapeutic Outcomes, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record